Moderna Trading Up 6.2% Shares of MRNA supply opened at $26.39 on Tuesday. Moderna Business Account (Free Report) Moderna, Inc, a biotechnology business, discovers, establishes, and markets messenger RNA rehabs and injections for the therapy of contagious illness, immuno-oncology, uncommon conditions, autoimmune, and cardio diseases in the United States, Europe, and globally. See Additionally Get News & Scores for Moderna Daily – Enter your e-mail address below to receive a succinct day-to-day recap of the most recent news and experts’ rankings for Moderna and related companies with MarketBeat.com’s FREE daily email e-newsletter.
Evercore ISI reduced their target cost on Moderna from $50.00 to $32.00 and set an “in-line” ranking on the supply in a study record on Friday, May Second. UBS Team cut their target cost on Moderna from $78.00 to $70.00 and set a “purchase” score on the stock in a study report on Friday, May 2nd. Moderna Trading Up 6.2% Shares of MRNA stock opened up at $26.39 on Tuesday. Moderna Firm Account (Free Report) Moderna, Inc, a biotechnology business, uncovers, develops, and advertises carrier RNA therapeutics and vaccinations for the treatment of infectious diseases, immuno-oncology, rare conditions, autoimmune, and cardiovascular conditions in the United States, Europe, and worldwide. See Additionally Obtain News & Scores for Moderna Daily – Enter your e-mail address below to get a succinct everyday recap of the most current news and experts’ ratings for Moderna and associated firms with MarketBeat.com’s FREE daily e-mail newsletter.